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1078–5884/00Results of Endovascular Repair of Inflammatory Abdominal
Aortic Aneurysms. A Report from the EUROSTAR DatabaseC. Lange,1 R. Hobo,2* L.J. Leurs,2 K. Daenens,3 J. Buth2 and H.O. Myhre1
On Behalf of the EUROSTAR Collaborators1University Hospital, Trondheim, Norway; 2The EUROSTAR Data Registry Center, Eindhoven,
The Netherlands; and 3The University Hospital, Leuven, BelgiumObjectives. To investigate the results following endovascular treatment of patients with inflammatory abdominal aortic
aneurysms (IAAA).
Design. Retrospective study based on the EUROSTAR registry.
Material and methods. Patients included in the EUROSTAR registry with IAAA (nZ52, 1.4%) were compared to those
having aneurysms without aortic fibrosis (nZ3613, 98.6%). The mean follow-up period in patients with IAAA was 23
months (range 1–60). In 11 of the patients detailed information on the effect of endovascular repair and perianeurysmal
fibrosis and ureteral entrapment was obtained by a dedicated questionnaire.
Results. Twelve patients (23%) with IAAA had preoperative impairment of renal function and five had known
hydronephrosis. Variables that were significantly associated with IAAA included younger age (p!.0001, mean difference
5.9, CI 3.7–7.9) and lower pulmonary risks score (OR 0.38, CI 0.19–0.74). At completion of the endovascular procedure,
device stenosis was more frequently observed in patients with IAAA (OR 18.1, CI 3.52–93.0). There were no differences with
regard to the rates of mortality, rupture or conversion in patients with IAAA and controls. In the majority, the aneurysm
size regressed irrespective of nature of aneurysm. Of the 11 patients with a detailed assessment three had deterioration of
renal function and three still had ureteral entrapment during follow-up.
Conclusion. Despite persistence of perianeurysmal inflammation in a proportion of patients operative and midterm results
of endovascular repair were comparable in the patients with inflammatory and standard AAA.Keywords: Abdominal aortic aneurysm; Inflammatory aneurysm; Endovascular repair.Introduction
Five to 10% of abdominal aortic aneurysms have an
inflammatory component (IAAA), characterized by a
white glistening fibrotic surface, a thickened aneurysm
wall and adhesions to neighbour structures. The
thickened wall can be observed on CT and is usually
in the range of 0.5–3 cm. Histologically, the muscular
and elastic structures of the media are replaced by
fibrotic tissue. Abundant lymphocytes and plasma
cells are present. Patients with IAAA often have
symptoms of abdominal or back pain. General
symptoms like fatigue and weight loss are also
common. The erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) are usually higher thaning author. Roel Hobo, MSc, Department of Vascular
arina Hospital, P.O. Box 1350, 5602 ZA Eindhoven, The
: eurostar@iae.nl
0363+ 08 $35.00/0 q 2005 Elsevier Ltd. All rights reserin patients with abdominal aortic aneurysm without
fibrosis.1–3 The fibrotic changes may represent a
difficulty during open surgery. This is reflected by a
longer operating time, a higher mortality and morbid-
ity and a greater need for blood transfusions when
compared to non-inflammatory aneurysm.4–6 Theor-
etically, therefore, endovascular repair (EVAR) could
be an option in the treatment of IAAA, however,
variation in outcome has been reported. In some cases,
a successful result with shrinking of the aneurysmal
sack has been observed.7–10 In contrast, others have
reported an increased inflammatory response follow-
ing EVAR in these patients (Fig. 1).11,12
Since, the indication for EVAR in patients with
IAAA remains controversial, the purpose was to
investigate the outcome in patients with IAAA treated
by EVAR and reported to the EUROSTAR register. The
results were compared with EVAR performed in
patients with non-inflammatory aortic aneurysm
reported to the same register.Eur J Vasc Endovasc Surg 29, 363–370 (2005)
doi:10.1016/j.ejvs.2005.01.004, available online at http://www.sciencedirect.com onved.
Fig. 1. CT examination 4 months after stentgraft repair of an
IAAA. Note thick layer of perianeurysmal fibrosis (arrows).
The left ureteric system became dilated after the procedure
and needed drainage (larger arrow).
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This report summarises the experience collated in the
EUROSTAR-database as of October 1996 to November
2003. The data of 3665 patients operated over a 7-year
period until October 2003 constituted the basis of this
analysis. The experience was obtained from 90 centers
in Europe and the contributors to this series are listed
in the Acknowledgement. The organisation of the
EUROSTAR Registry and reports on various aspects
after EVAR has been published previously.13–15 All
patients had a minimum follow-up period of 1 month.
The mean follow-up period in patients with IAAAwas
23 months (range 1–60). Patients with an aortic
aneurysm smaller than 4.0 cm in diameter, including
those with large iliac aneurysms, were excluded from
this study cohort. An exception of this condition was
IAAA, for which a diameter threshold for inclusion of
3.0 cm was used.
To assess the effect of IAAA on the early and mid-
term outcome after EVAR the study cohort was
subdivided according to the information provided on
the case record forms (CRFs) about the inflammatory
status of the aneurysm: patients with inflammatory
aneurysms (IAAA) and patients with non-inflamma-
tory aneurysms (non-IAAA). Specific details regard-
ing the increase or decrease in the inflammatory
response at follow-up were based on CRP, ESR and
CT. Patients with IAAA were identified and their
details derived from the free text fields in the CRFs as
there were no queries specifically directed at IAAA. InEur J Vasc Endovasc Surg Vol 29, April 2005addition, all centers participating in the EUROSTAR
Registry received a letter requesting identification of
patients with IAAA. To retrieve additional detailed
data related to IAAA, a questionnaire was sent to the
institutions whose records indicated endovascular
treatment of patients with inflammatory aneurysms.
Additional information regarding follow-up CTexam-
inations and inflammatory serum markers for 11
patients were completed and returned to the EURO-
STAR Data Registry Center.
Inclusion criteria as defined in the EUROSTAR
registry protocol, comprised elective treatment of
AAA with vascular anatomy suitable for the implan-
tation of a stent-graft. Baseline data, including co-
morbidity, estimate of unfitness for open repair,
anatomic aspects and operative details were recorded
by the participating institutions on CRF’s and sub-
mitted for inclusion to the Data Registry Center.
Findings at follow-up visits, which involved clinical
examination, CT-assessment or (in 5% of the visits)
angiography, MRI or ultrasound, were recorded in
data forms and returned at regular intervals to the
Data Registry Center for processing and analysis.
There was no outside monitoring of the centers or
involvement of a core laboratory for the evaluation of
CT-scanning or other imaging studies. Follow-up
visits according to the protocol were scheduled at 1,
6, 12, 18 and 24 months and annually thereafter.
Reminders for overdue follow-up data were regularly
sent to the participating institutions. Outcome was
reported according to the guidelines from the Society
for Vascular Surgery/American Association for Vas-
cular Surgery (SVS/AAVS).16 Deaths were classified as
aneurysm-related or all-cause deaths.17 The latter
included death related to co-morbidity and conditions
unrelated to the aneurysm. Aneurysm-related deaths
included all deaths within 30 days and deaths that
occurred as a result of aneurysm rupture, endograft
infection or death within 1 month after a secondary
surgical procedure for late complications of the
aneurysm.
Other outcome events observed during follow-up
included endoleaks, migration, severe device kinking,
occlusion, stenosis and aneurysmal growth. Only
endoleaks that were identified at 1 month and there-
after were included in the analysis, while endoleaks at
the completion angiography were considered. Endo-
leaks were classified into type I, II and III as previously
described.18 In cases with different types of endoleaks
observed at different follow-up periods, types I and III
were considered above type II for the analysis. The
interval between the date of surgery and the date on
which the endoleak was identified for the first time,
was used for the life-table analysis.
Table 1. Patient characteristics at the time of operation
Inflammatory Non-inflammatory p-value
NZ52 NZ3613
Age (years, meanGsd) 65.8 (G10.1) 71.6 (G7.6) !.0001
Length of follow-up (months,
meanGsd)
22.8 (G18.2) 17.9 (G14.9) .0205
Ratio male:female gender 96.1:3.9 94.4:5.6 .59
ASA classification III, IIIC/IV 25 (48.1%) 1875 (51.9%) .58
ABI%0.87* 2 (9.1%) 385 (20.6%) .18
Diabetes 5 (9.6%) 418 (11.6%) .66
Smoking 19 (36.5%) 817 (22.6%) .0175
Hypertension 24 (46.2%) 2272 (62.9%) .0133
Hyperlipidemia 14 (26.9%) 1438 (39.8%) .06
Cardiac disease 23 (44.2%) 2146 (59.4%) .0272
Carotid artery disease 8 (15.4%) 551 (15.3%) .98
Renal insufficiency 12 (23.1%) 666 (18.4%) .39
Reduced pulmonary function 11 (21.2%) 1497 (41.4%) .0032
Previous laparotomy 17 (32.7%) 967 (26.8%) .34
Obesity 13 (25.5%) 894 (24.8%) .91
Unfit for open AAA or general
anesthesia
12 (23.1%) 862 (23.9%) .90
* Ankle-brachial index is missing in a considerable number of patients.
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deviation for continuous variables. Discrete variables
were represented as proportions (%) of the study
group. Preoperative patient characteristics, co-morbid
factors, aneurysmal morphology at the time of the
initial procedure, and details regarding the procedure
and devices are correlated with the defined study
groups by univariate analysis. Differences in findings
between study groups were assessed by Chi-square
tests for discrete variables and by Student’s t and
Mann–Whitney tests for continuous variables. A p-
value!.05 was considered to represent a significant
difference. Cumulative rates of freedom-from-aneur-
ysm-related deaths, overall deaths, aneurysms rup-
ture, conversion to open repair, endoleaks and
increase of inflammatory reaction were assessed by
life-table analysis. Significant differences between
study groups were assessed by log-rank testing.
Variables with clinical relevance were entered in a
multivariate Cox-analysis to assess independent
associations with late outcome. Postoperative change
in aneurysm size in the IAAA group was compared to
preoperative measurement by a paired T-test. All
statistical analyses were performed with SAS Statisti-
cal Software (version 8.0, SAS Institute Inc., Cary, NC).Results
The 3665 patients, 3461 male and 204 female, ranged in
age from 43 to 95 years. Fifty-two patients (1.4%) had
an IAAA, all diagnosed by CT, and 3613 (98.6%) a non-
IAAA. The mean age in patients with IAAA wasapproximately 6 years less than in the other patients
(Table 1). Other significant differences in patient
characteristics included a higher incidence of smoking
(pZ.0175), and lower incidence of hypertension (pZ
.0133), better cardiac condition or less previous cardiac
events (pZ.0272) and less pulmonary disease (pZ
.0032) in the IAAA group. Regarding existing anatomy
no differences were observed in angulation in the
aneurysm neck (pZ.12), the aneurysm itself (pZ.18) or
the iliac arteries (pZ.08). The infrarenal neck was
similar with regard to diameter (pZ.87) and length
(pZ.11) in the two study groups. The aneurysm had
comparable diameters (pZ.78) and patency of iliac
and hypogastric arteries.
Operating time was 140 min (45–345) in the group
with IAAA compared to 133 min (25–660) in non-
IAAA (ns). In the former group 47 had bifurcated
endografts, one had a tube graft while four had
aortouniiliac grafts. Extraanatomic bypasses were four
times as frequent in the group with IAAA compared to
non-IAAA (Table 2). Device or limb stenosis during
the procedure occurred almost 18 times more fre-
quently in the group with IAAA (pZ.0005). Device
migration as observed on the intraoperative angio-
gram did not occur in any of the patients with IAAA
and in 40 of the patients with non-IAAA (1.1%). No
differences were observedwith regard to length of stay
in hospital, prevalence of endoleak or the incidence of
primary conversion to open surgery. Only blocking of
one iliac artery was significantly different in the two
study groups. Thirteen (25%) occurred in IAAA (nine
intentional and four inadvertently) and 488 (13.5%) in
non-IAAA, pZ.0100.Eur J Vasc Endovasc Surg Vol 29, April 2005
Table 2. Procedural details and predischarge outcomes
Inflammatory Non-inflammatory p-value*
NZ52 NZ3613
Failure to complete procedure 1 (1.9%) 58 (1.6%) .69
Extra-anatomic bypass 2 (3.9%) 32 (0.9%) .0086
Device related complications 6 (11.5%) 261 (7.2%) .16
Device migration 0 (0.0%) 48 (1.3%) –
Device/device limb stenosis 2 (3.9%) 9 (0.3%) .0005
Hypogastric artery occlusion 13 (25.0%) 488 (13.5%) .0100
Arterial complications 2 (3.9%) 128 (3.6%) .72
Systemic complications 4 (7.7%) 438 (12.1%) .63
Access site complications 2 (3.9%) 241 (6.7%) .65
Type I endoleak 1 (1.9%) 158 (4.4%) .50
Type II endoleak 6 (11.5%) 328 (9.1%) .65
Type III endoleak 2 (3.9%) 88 (2.4%) .62
Death%30 days 1 (1.9%) 81 (2.2%) .66
Conversion%30 days 0 (0.0%) 42 (1.2%) –
Rupture%30 days 0 (0.0%) 1 (0.03%) –
* Adjusted for age, smoking, hypertension and cardiac and pulmonary risk status.
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The first-month mortality in the entire cohort was 2.2%
(82 patients). There was no significant difference
between the two study groups. There were no
significant differences with regard to systemic com-
plications (cardiac, cerebral, pulmonary, renal, hepa-
tobiliary, bowel and sepsis) in the two study groups.
Minor complications from the access sites and lower
limb arteries were similar in the group with IAAA and
non-IAAA (3.9 and 6.7%, respectively; ns). Arterial
thrombosis occurred only in the group of patients with
non-IAAA (0.8%). An increased periaortic inflamma-
tory response was observed in 12% and a decreased
periaortic inflammation in 17% of all patients with
IAAA.Late outcome
There were no differences in the incidence of type I, II
and III endoleaks. The percentage of patients with
aneurysmal growth was similar in the two groups.
Device migration, kinking, stenosis or thrombosis was
comparable in both groups. No differences were
observed with regard to all-cause death, aneurysm-
related death, rupture and conversion to open repair
(Table 3). Of 47 patients with IAAA, diameter
measurements were recorded during follow-up. A
regression of the aneurysm was observed in 41 (87%,
pZ.0001) (Fig. 2). With regard to aneurysm shrinkage,
no difference was observed between patients with and
without IAAA.Detailed information on 11 of the patients with IAAA
At presentation hydronephrosis was present in fiveEur J Vasc Endovasc Surg Vol 29, April 2005patients (45%). Previous ureteric procedures had been
performed in four patients (36%) (Table 4). Abdominal
pain was present in 63% of the patients who had
additional and detailed data provided by the ques-
tionnaire. Worsening of renal function in this sub-
group was observed in the early postoperative period
in 9% and in the late postoperative period in 27%.
Postoperative ureteric stenting or ureterolysis was
performed in two (18%) of these patients. No patients
needed dialysis early or late postoperatively. Serum
concentration of urea and creatinine decreased in these
11 patients, although not significantly. The ESR
decreased during the early postoperative period.
However, later it increased again to preoperative
levels. The CRP levels decreased in the late post-
operative phase compared to the preoperative phase.
Aneurysm wall thickness decreased in the 11 patients
with detailed information from 21 mm preoperatively
to 17 mm early and 13 mm late postoperatively.
Ureteric entrapment was observed in 45% of the
patients preoperatively, decreasing to 27% after the
procedure. In one patient the ureteric obstruction
which was present preoperatively remained trouble-
some after operation with continued requirement for
ureteric stenting.Discussion
Taking into consideration that open surgery for IAAA
is often challenging from a technical point of viewwith
reported higher mortality and complication rate,2,4,5
the present investigation indicates that with respect to
exclusion of the aneurysm from the circulation, EVAR
is a feasible method with promising early and
midterm results. We have not observed a higher
mortality or morbidity rate than for other aneurysms
Table 3. Late outcomes
Freedom of (4 years) Inflammatory Non-inflammatory p-value*
NZ52 (%) NZ3613 (%)
Type I endoleak 100.0 90.3 .97
Type II endoleak 77.8 83.8 .50
Type III endoleak 97.8 92.4 .86
Device migration 95.7 86.7 .59
Kinking 100.0 96.7 .99
Stenosis/thrombosis 97.9 94.5 .52
Aneurysm growthR8 mm 84.8 83.3 .22
Secondary endovascular intervention 83.4 88.8 .23
Death 92.8 81.6 .69
AAA-related death 98.1 96.2 .97
Conversion 95.7 94.3 .68
Rupture 100.0 98.6 .99
* Adjusted for age, smoking, hypertension and cardiac and pulmonary risk status.
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open surgery for IAAA. A mortality rate of 1.9% must
be regarded as satisfactory, especially considering that
23.1% of the patients with IAA were unfit for open
surgery. Systemic complications also were
comparable.
While exclusion of the aneurysm seems to be
obtained by EVAR in most cases, the effect on the
fibrosis itself is less clear. Postoperatively both
increased and decreased periaortic inflammation was
observed on follow-up CT-scans although significant
increase was only observed in six patients. The cause
of this variable reaction regarding the fibrosis remains
unknown. It is possible that the increased fibrosis in
some cases could be related to the so-called ‘post
implantation reaction’ occasionally seen in patients
treated with EVAR. It would be of importance to
follow these changes over the years, even if the renal
function is not deteriorated. Following open oper-
ation, the fibrosis is decreasing in about 75% of the
cases.19,20 Although rare, increased fibrosis has also
been reported following open surgery.21,22 In patients
with ureteral stenosis, regular CT-surveillance also
seems indicated after open surgery.22
Even if the preoperative anatomy was similar in theTable 4. Additional information on 11 patients with inflammatory an
Preoperative
Clinical
Worsening of renal function 5 (45%)
Ureter stent/urethrolysis 4 (36%)
Need for dialysis –
Laboratory values meanGSD
Urea (mmol/l) 22.4G21.7
Creatinine (mmol/l) 402G537
ESR (mm/h) 50G31
CRP (mg/l) 107G81
CT findings
Wall thickness (mm) 20.8G15.9
Obvious decrease –
Ureter entrapment 5 (45%)two groups, there was an increased rate of graft limb
stenosis in the IAAA group. As there were no
significant anatomical differences between the two
groups, the higher incidence of graft limb stenosis-
occlusion may be related to the distal landing zone in
the external iliac artery. This finding is associated with
the more frequent overlapping of the hypogastric
artery by the device limb in the IAAA group. One
femorofemoral crossover was performed due to
occlusion at the time of procedure. It is possible that
the iliac arteries where encapsulated by fibrotic tissue
and that the arterial wall as well as the aneurysm wall
was stiffer than in patients with non-inflammatory
aneurysms. Thus, modelling of the endoprosthesis
with a balloon catheter after deployment could
become more difficult. It is also possible that IAAA is
a separate disease entity23 with a higher incidence of
autoimmune diseases24 and a higher metabolic
activity than non-inflammatory AAA.25 However,
although statistically significant, the total number of
graft limb obstructions was small and further inves-
tigation of this particular phenomenon is necessary.
Hydronephrosis with or without ureteric pro-
cedures were frequently observed in the smaller
subset with detailed information. It is likely that thiseurysms
Early postoperative Late postoperative
1 (9%) 3 (27%)
1 (9%) 1 (9%)
0 (0%) 0 (0%)
meanGSD meanGSD
10.0G3.1 12.4G6.2
118G34 140G56
34G35 45G50
66G45 33G45
17.4G18.1 12.8G18.4
6 (55%) 6 (55%)
4 (36%) 3 (27%)
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Fig. 2. Diameter changes in 47 patients with IAAA. The
regression of aneurysm size in this group was significant
(pZ.0001).
C. Lange et al.368was a selected group of patients with a high incidence
of ureteric complications. Late postoperative worsen-
ing of renal function was present in 27%. These
findings suggest that EVAR alone may not be the
optimal treatment for all patients with IAAA. Possibly
some patients with IAAA and ureteral stenosis might
need post-EVAR ureterolysis, omental wrapping of the
ureters or perhaps corticosteroid therapy, although
this has not usually been considered necessary
following open surgery. On the basis of the present
analysis EVAR may especially be considered in
patients with IAAA who have a high risk for open
repair or in those who do not have ureteral stenosis.
However, more studies are needed to determine
whether EVAR is also the first-choice in the treatment
of good-risk patients with IAAA.
The present study has several limitations including
its retrospective nature and that it is based on
questionnaires. It should be noted that the EUROSTAR
database is not specifically designed for analysis of the
typical pathology associated with IAAA. Neverthe-
less, we could identify a subgroup of patients with
IAAA treated by EVAR, which is the largest series
published in the literature so far. To assess some
aspects of this typical condition in greater detail an
additional questionnaire was mailed to the partici-
pants who had enrolled IAAA patients. This ques-
tionnaire resulted in more information in a proportion
of our entire study group. The incidence of IAAA of
1.4% is lower than in most series treated with open
surgery where an incidence of 5–10% has been
reported.5,6 Although unlikely, a lower incidence of
IAAA in the present series could be explained by aEur J Vasc Endovasc Surg Vol 29, April 2005smaller number of patients originally found suitable
for EVAR according to the preoperative CT-scans or
arteriograms, possibly due to the previously men-
tioned higher incidence of iliac aneurysms. It is also
possible that more patients than we have detected in
the registry so far, have an IAAA.
It should also be taken into consideration that about
23% of the patients were found unfit for open surgery
and it is possible that some vascular surgeons did not
find EVAR suitable treatment for patients with IAAA,
especially in the early phase of our investigation. Thus,
the group of patients unfit for open surgery perhaps
consists of two subgroups; those considered unfit due
to risk factors and those considered unfit because they
had IAAA. This could explain why the incidence of
patients unfit for open surgery were equal in the two
groups, despite patients with IAAA being significantly
younger. There are also differences in the classification
of IAAA in patients treated by EVAR and those treated
by open surgery. During open surgery the visual
appearance of IAAA can be supplemented by a biopsy,
whereas patients who are treated for EVAR must be
classified according to the CT-scans only. Therefore,
more inflammatory aneurysms may be identified
during open surgery. Finding an IAAA by surprise is
not rare. This may explain the relatively low incidence
of IAAA in this study.
In conclusion, the results following EVAR of
patients with IAAA and patients with non-IAAA
were largely similar with regard to early and mid-term
results. EVAR is a feasible method to exclude IAAA
from the circulation. Perianeurysmal fibrosis did not
regress in a proportion of patients, however, clinical
outcome was favourable. The effect upon the fibrotic
changes needs to be studied more thoroughly
especially in patients with ureteric complications to
define the exact role of EVAR in patients with
inflammatory aortic aneurysms.Acknowledgements
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